Hepatocellular carcinoma (HCC) is a primary malignancy of the liver and mainly occurs in patients having chronic liver disease and cirrhosis. Egypt ranks the third and15th most populous country in Africa and worldwide, respectively. In Egypt, the health authorities consider HCC as the most challenging health problem. The number of HCC patients increased twofold over a decade. HCV cure by DAAs is expected to reduce the incidence of chronic liver disease, liver cirrhosis, HCC, which result in decreased liver-related mortality. DAAs in patients with liver cirrhosis created a heated debate about the risk of HCC occurrence and recurrence after viral cure.HCV cure by DAAs benefits patients as the liver inflammation decreased, fibrosis reversed, as well as a decreasing incidence of liver transplantation and liver-related extra hepatic complications.The effect of sustained virologic response (SVR) from direct-acting antiviral (DAA) and interferon-based treatments on hepatocellular carcinoma (HCC) risk was evaluated.

Hepatocellular Carcinoma